Who are probiotic ® pur's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Combizym + Bifidobacteri, Lactobacillus Reuteri Probiotic, Lactobacillus casei, Gynomunal® gel, Probiotics (Lacidofil®), Akkermansia muciniphila + Infliximab.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/probiotic-pur.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

probiotic ® pur — Competitive Intelligence Brief

probiotic ® pur (probiotic ® pur) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Probiotic. Area: Gastroenterology / Immunology.

phase 3 Probiotic Gastroenterology / Immunology Small molecule Live · refreshed every 30 min

Target snapshot

probiotic ® pur (probiotic ® pur) — Yuzuncu Yil University. Probiotic PUR restores beneficial gut microbiota to improve intestinal barrier function and modulate immune responses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
probiotic ® pur TARGET	probiotic ® pur	Yuzuncu Yil University	phase 3	Probiotic
Combizym + Bifidobacteri	Combizym + Bifidobacteri	RenJi Hospital	marketed	Enzyme and probiotic combination
Lactobacillus Reuteri Probiotic	Lactobacillus Reuteri Probiotic	Liaquat National Hospital & Medical College	marketed	Probiotic
Lactobacillus casei	Lactobacillus casei	Hospital Cristo Re	marketed	Probiotic
Gynomunal® gel	Gynomunal® gel	Derming SRL	marketed	Vaginal probiotic/microbiota restorer
Probiotics (Lacidofil®)	Probiotics (Lacidofil®)	Chuncheon Sacred Heart Hospital	marketed	Probiotic
Akkermansia muciniphila + Infliximab	Akkermansia muciniphila + Infliximab	Chinese Medical Association	marketed	Combination therapy: probiotic + TNF-α inhibitor	TNF-α (infliximab component); gut microbiota modulation (Akkermansia muciniphila component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Probiotic class)

BioBalance Corporation · 1 drug in this class
Biocodex · 1 drug in this class
CD Pharma India Pvt. Ltd. · 1 drug in this class
CHU de Quebec-Universite Laval · 1 drug in this class
Chuncheon Sacred Heart Hospital · 1 drug in this class
Dow University of Health Sciences · 1 drug in this class
Federico II University · 1 drug in this class
Fundación Hospital de Pediatría Prof. Dr. Juan P. Garrahan · 1 drug in this class
GWT-TUD GmbH · 1 drug in this class
Aga Khan University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). probiotic ® pur — Competitive Intelligence Brief. https://druglandscape.com/ci/probiotic-pur. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab